

Iluvien (fluocinolone acetonide intravitreal implant)

Override(s)	Approval Duration
Prior Authorization	One time

Medications	Dosing Limit
Iluvien (fluocinolone acetonide) 0.19 intravitreal implant	One intravitreal implant (0.19 mg) per eye; each eye may be treated as frequently as every 36 months

APPROVAL CRITERIA

Requests for Iluvien (fluocinolone acetonide intravitreal implant) may be approved if the following criteria are met:

- I. Individual has a diagnosis of diabetic macular edema; **AND**
- II. Individual has previously been treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure;

OR

- III. Individual has a diagnosis of chronic (duration of 1 year or more) non-infectious uveitis affecting the posterior segment of the eye.

Requests for Iluvien (fluocinolone acetonide intravitreal implant) may not be approved for the following criteria:

- I. Individual has active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva (such as epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella), mycobacterial infections and fungal diseases; **OR**
- II. Individual has glaucoma with a cup to disc ratio of greater than 0.8; **OR**
- III. When the above criteria are not met and for all other indications.

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2025; Updated periodically.
4. American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Diabetic Retinopathy. February 2025.
5. American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Retinal Vein Occlusions. February 2025.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.